普拉克索联合左旋多巴治疗帕金森病的临床效果及安全性

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect and safety of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease. Methods From January 2017 to December 2018, 100 patients with Parkinson′s disease treated in our hospital were selected as subjects, and divided into control group (n=50) and study group (n=50) by random lottery method. Patients in the control group were treated with Levodopa, while patients in the study group were treated with Pramipexole combined with Levodopa. The clinical treatment effect of patients of the two groups was compared, the concise health status scale (SF-36) scores and the Hamilton depression scale (HAMD-17) scores of the two groups before and after treatment were compared, and the occurrence of adverse reactions of patients in the two groups was compared. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, indexes of SF-36 scores in the study group were higher than those in the control group, and the differences were statistically significant (P＜0.05). After treatment, the HAMD-17 score in the study group was lower than that in the control group, with statistically significant difference (P＜0.05).The total incidence of adverse reactions in the study group was lower than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion The application of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease can effectively improve the symptoms of the disease, improve the clinical efficacy, and has high safety. It has important clinical application value.

Key words： Pramipexole Levodopa Parkinson′s disease Clinical effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Chun-li
	XU Tian-yin
	WANG Yi-ning

Cite this article:

MA Chun-li,XU Tian-yin,WANG Yi-ning. Clinical efficacy and safety of Pramipexole combined with Levodopa in the treatment of Parkinson′s disease[J]. 中国当代医药, 2020, 27(19): 81-84.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I19/81

[5]	侯宇，姜丽杰，薛天宇，等.左旋多巴联合普拉克索对帕金森运动障碍患者的应用效果[J].中国合理用药探索，2019，16（3）：101-104.
[6]	刘丹阳.左旋多巴联合普拉克索治疗帕金森病的疗效及对运动功能的影响[J].北方药学，2019，16（4）：92-93.
[7]	祁萌，李攀攀，刘永芳.左旋多巴联合普拉克索治疗帕金森病的疗效及对血清代谢组学指标的影响[J].国际医药卫生导报，2017，23（23）：3747-3749.
[8]	刘学昌.左旋多巴联合普拉克索对帕金森病患者应激反应的影响[J].中国实用神经疾病杂志，2018，21（16）：1792-1797.
[1]	于莹，张娴.普拉克索对脑梗死后帕金森病的临床疗效及安全性分析[J].中国现代医生，2019，57（11）：126-128，132.
[2]	申红菊.左旋多巴联合普拉克索治疗帕金森病的有效性及作用机制[J].当代医学，2019，25（11）：135-137.
[3]	钟丹.探讨左旋多巴联合普拉克索治疗帕金森病的临床疗效及安全性[J].中西医结合心血管病电子杂志，2019，7（2）：192-193.
[4]	张璐.探讨普拉克索联合左旋多巴治疗帕金森病的临床疗效[J].中国合理用药探索，2019，16（4）：142-144.
[9]	韩国辉，姬松波.左旋多巴联合普拉克索治疗帕金森病的疗效及对改善运动功能的影响分析[J].北方药学，2018，15（11）：86-87.
[10]	吴琼.左旋多巴联合普拉克索治疗帕金森病痴呆效果观察[J].中国实用乡村医生杂志，2018，25（6）：68-69，72.
[11]	陈敏.美多芭联合盐酸普拉克索治疗帕金森病非运动症状的临床效果[J].广西医学，2019（14）：1784-1786.
[12]	陈荣平.左旋多巴联合普拉克索治疗帕金森病的临床疗效分析[J].黑龙江医药，2018，31（2）：331-333.
[13]	周永，陈蓝，戴杰，等.普拉克索联合左旋多巴治疗帕金森病的临床疗效及安全性[J].药物评价研究，2018，41（12）：2262-2265.
[14]	王瑛，孙圣刚，朱遂强，等.普拉克索缓释剂和速释剂治疗中国帕金森病患者的疗效及安全性对比评估：一项随机、双盲、双模拟平行组研究[J].中华神经科杂志，2015，48（4）：287.
[15]	李霞.普拉克索治疗帕金森病180 例临床探讨[J].山西医药杂志，2018，47（19）：2347-2349.
[16]	龙旭，保云梅.普拉克索辅助治疗帕金森病的效果及安全性[J].中外医学研究，2019，17（15）：25-27.
[17]	戴毅，吴玉泉，成军，等.普拉克索联合恩他卡朋治疗对帕金森病非运动症状的临床疗效及安全性评价[J].中国临床药理学杂志，2015，6（20）：1996-1998.